Investigation of the Antioxidant Status in Multiple Myeloma Patients: Effects of Therapy

  • Mehdi, Wesen A. (Department of Chemistry, University of Baghdad) ;
  • Zainulabdeen, Jwan A. (Department of Chemistry, University of Baghdad) ;
  • Mehde, Atheer A. (Department of Acceptable Analysis, Health and Medical Technical College)
  • Published : 2013.06.30


Background: Multiple myeloma is a malignant silent incurable plasma cell disorder. The present study aimed to assessed the activation of the oxidative stress pathway in afected patients Materials and Methods: Advanced oxidation protein products (AOPPs), malondialdehyde (MDA), adenosine deaminase (ADA), total antioxidant capacity (TAC) levels, glutathione, ascorbic acid (vitamin C), ${\alpha}$-tocopherol (vitamin E) in addition to related enzymes glutathione peroxidase (GSH-Px), glutathione reductase (GSH-R) and superoxide dismutase (SOD) were analyzed in sixty patients with multiple myeloma before and after one month treatment with induction therapy. Results: The results of the study showed a significant elevation in AOPPs, MDA, ADA levels in patients with multiple myeloma before and after treatment in comparison to healthy control samples In contrast TAC glutathione, vitamin C and E, and the antioxidant enzymes levels were decreased significantly. On comparing samples of MM patients after treatment, there was significant increase of TAC glutathione, vitamin C and E, and the antioxidant enzymes in parallel with decreasing AOPPs, MDA and ADA levels in comparison with samples of patients before treatment. Conclusions: The results indicate oxidative stress and DNA damage activity increase in MM and are alleviated in response to therapy.


  1. Alexander DD, Mink PJ, Adami HO, et al (2007). Multiple myeloma: a review of the epidemiologic literature. Int J Cancer, 120, 40-61.
  2. Beutler E, Duron O, Kelly BM (1963). Improved method for the determination of blood GSH. J Lab Clin Med, 61, 882-8.
  3. Campanella A, Santambrogio P, Fontana F, et al (2012). Iron increases the susceptibility of multiple myeloma cells to bortezomib. Haematologica J, 10, 3324.
  4. Chatterjea MN, Shinde R (2007). Textbook of medical biochemistry. 7th edn. Jaypee brothers medical publications, New Delhi. pp. 92-113.
  5. Dierickx PJ (1999). Glutathione-dependent cytotoxicity of the chloroacetanilide herbicides alachlor, metolachlor, and propachlor in rat and human hepatoma-derived cultured cells. Cell Biol Toxicol, 15, 325-2.
  6. Estakhri R, Hajipour B, Majidi H, Soleimani H (2013). Vitamin E ameliorates cyclophosphamide induced nephrotoxicity. Life Sci J, 10, 308-13.
  7. Giusti G (1974). Adenosine deaminase. In: Bergneyer HU, Methods of enzymatic analysis. 2nd Edn., Academic Press Inc., New York, pp. 1092-8.
  8. Goljan E, Sloka KI (2008). Laboratory testing in clinical medicine. 1st edn. Mosby Elsevier Inc Publications, USA. pp. 283-6.
  9. Hideshima T, Anderson KC (2002). Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer, 2, 927-37.
  10. Ishikawa K, Takenaga K, Akimoto M, et al (2008). ROSgenerating mitochondrial DNA mutations can regulate tumor cell metastasis. Science, 320, 661-4.
  11. Kaya E, Keskin L, Aydogdu I, et al (2005). Oxidant/antioxidant parameters and their relationship with chemotherapy in hodgkin's lymphoma. J Int Med Res, 33, 687-92.
  12. Krzystek-Korpacka M, Patryn E, Boehm D, et al (2008). Advanced oxidation protein products (AOPPs) in juvenile overweight and obesity prior to and following weight reduction. Clinical Biochemistry, 41, 943-9.
  13. Kyle RA, Rajkumar SV (2004). Multiple myeloma. N Engl J Med, 351, 1860-73.
  14. Kyle RA, Rajkumar SV (2004) Plasma, cell disorders. In: Goldman L, Ausiello D, editors. Cecil textbook of medicine. Chapter 196. 2nd edn. Philadelphia, W.B. Saunders, pp. 1184-6.
  15. Kyle RA, Rajkumar SV (2008). Multiple myeloma. Blood, 15, 2962-72.
  16. Kyle RA, Rajkumar SV (2009). Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia, 23, 3-9.
  17. Lee K, Koon IT, Mee AS (1975). A new colorimetric method for the determination of NADH/NADPH dependent GSSGRed in erythrocyte and in plasma. Clinica Chimica Acta, 58, 101-8.
  18. Lenhinger AL (2005). Principles of biochemistry" 4th edn., H. Freeman and Company. New York, pp. 94.
  19. Marnett LJ, Riggins JN, West JD (2003). Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J Clin Invest, 111, 583-93.
  20. Marquez A, Villa-Trevino S, Gueraud F (2007). The LEC rat: a useful model for studying liver carcinogenesis related to oxidative stress and inflammation. Redox Rep, 12, 35-9.
  21. Mehde A, Mehdi W, Jasim A (2013). Study several biochemical parameters into patient's with hepatitis B virus global. J Med Res Diseases, 13, 210.
  22. Camilla R, Suzuki H, Dapra V, et al (2011). Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathyst. Clin J Am Soc Nephrol, 6, 1903-11
  23. Misra HP, Fridovich I (1972). The role of superoxide anion in the auto oxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem, 247, 3170-5.
  24. Munshi N (1997). Immunoregulatory mechanisms in multiple myeloma. Hematol Oncol Clin North Am, 11, 51-69.
  25. O'Connell TX, Horita TJ, Kasravi B (2005). Understanding and Interpreting serum protein electrophoresis. Am Fam Physician, 71, 105-12.
  26. Ottaviano FG, Handy, DE, Loscalzo J (2008). Redox regulation in the extracellular environment. Circ J, 72, 1-16.
  27. Pleban PA, Munyani A, Beachum J (1982). Determination of selenium concentration and glutathione peroxidase activity in plasma and erythrocytes. Clin Chem, 28, 311-6.
  28. Raab MS, Podar K, Breitkreutz I, et al (2009). Multiple myeloma. Lancet, 374, 324-39.
  29. Ravaud P, Thepot C, Auleley GR, Amor B (1996). Imaging of multiple myeloma. Ann Med Interne, 147, 370-5.
  30. Rice-Evans C, Mille NJ (1994). Total antioxidant status in sera and body fluids. In: Methods in Enzymology. New York: Academic Press, pp. 279-93.
  31. Satoh K (1978). Plasma lipid peroxide in cerebrovascular disorders determined by new colorimetric method. Clin Chim Acta, 90, 37-43.
  32. Sharma A, Tripathi M, Satyam A, Kumar L (2009). Study of antioxidant levels in patients with multiple myeloma. Leuk Lymphoma, 50, 809-15.
  33. Waris G, Ahsan H (2006). Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinogenesis, 14, 14-21.
  34. Xuan-li Xu, Yi-hong S, Shen Q, Jian-ying Z (2013). Case of bilateral pleural effusion as the first sign of multiple myeloma. Eur J Med Res, 18, 7.

Cited by

  1. Correlation of Inhibin and Several Antioxidants in Children with Acute Lymphoblastic Leukemia vol.15, pp.12, 2014,
  2. Antioxidant value and Antiproliferative Efficacy of Mitragynine and a Silane Reduced Analogue vol.15, pp.14, 2014,
  3. Pu-erh Tea Powder Preventive Effects on Cisplatin-Induced Liver Oxidative Damage in Wistar Rats vol.15, pp.17, 2014,
  4. The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma vol.4, pp.7, 2014,
  5. Multiple Myeloma: a Retrospective Analysis of 61 Patients from a Tertiary Care Center vol.17, pp.4, 2016,
  6. International Scoring System in Symptomatic Multiple Myeloma: Experience from a Tertiary Care Center vol.17, pp.4, 2016,
  7. Assessment of serum thiol/disulfide homeostasis in multiple myeloma patients by a new method vol.22, pp.6, 2017,
  8. Intravenous Vitamin C for Cancer Therapy – Identifying the Current Gaps in Our Knowledge vol.9, pp.1664-042X, 2018,
  9. Copper and zinc in stage I multiple myeloma: relation with ceruloplasmin, lipid peroxidation, and superoxide dismutase activity vol.0, pp.0, 2018,